Awaiting PCAC · Jul 2026
BPC-157 · Texas (US)Removed from Cat-2 on April 22, 2026. PCAC review scheduled July 23-24, 2026. Not yet legally compoundable.
Removed from Category 2 by the FDA on April 22, 2026 — meaning the FDA no longer flags significant safety concerns — but this is NOT permission to compound. The peptide must clear PCAC review (July 23-24, 2026) and FDA notice-and-comment rulemaking (typically 12-18 months) before licensed 503A pharmacies can legally produce it. As of today, the legitimate-prescription pathway is closed; informal sourcing is research-grey-market and unregulated for human use.
PATH503A compounding
WINDOWPCAC Jul 23–24
CONTEXTTX — no state ban
What to do
01Track the PCAC July 23-24, 2026 outcome — Stack's /pcac-tracker will publish same-day status updates.
02Submit a public comment to the FDA docket (deadline July 9, 2026 for the July meeting).
03Discuss with your provider whether an FDA-approved alternative exists for your goal (e.g., Tesamorelin for fat-loss indications).
04Do not source from research-use-only vendors based on the April 22 news — that channel remains unregulated.
Jurisdiction contextTexas operates at the federal floor — broader telemedicine prescribing, no additional state-level peptide restrictions beyond federal rules. Currently the friendliest large-state market for compounded peptides.